Tech Company Financing Transactions
Immune-Onc Therapeutics Funding Round
Immune-Onc Therapeutics closed a $73 million Series B funding round on 4/1/2021. Investors included Ocean Pine Healthcare Fund, Northern Light Venture Capital and Octagon Investments Fund.
Transaction Overview
Company Name
Announced On
4/1/2021
Transaction Type
Venture Equity
Amount
$73,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will allow Immune-Onc to advance its portfolio of blood cancer and solid tumor immunotherapies targeting myeloid checkpoints with a focus on the LILRB family.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
795 San Antonio Rd.
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
Immune-Onc Therapeutics, Inc. is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charlene Liao
Chief Medical Officer
Paul Woodard
Founder
Guo-Liang Yu
VP - Bus. Development
Ji Li
VP - Bus. Development
An Song
Browse more venture capital transactions:
Prev: 4/1/2021: Uniphore venture capital transaction
Next: 4/1/2021: Pipe venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs